文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

PSMA-PET/CT引导的前列腺癌放疗强化(PSMAgRT):一项2期随机对照试验的病灶检出率、对癌症管理的影响及早期毒性结果

PSMA-PET/CT-Guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): Findings of Detection Rate, Effect on Cancer Management, and Early Toxicity From a Phase 2 Randomized Controlled Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-01-11

这项2期随机对照试验在2个机构纳入计划接受放疗的前列腺癌患者,随机分配至PSMAgRT组或对照组,覆盖寡转移、高危、放疗后挽救和前列腺切除术后挽救4个分层。PSMA-PET/CT在45.5%寡转移、39.5%高危、14.3%放疗后挽救和51.6%前列腺切除术后挽救患者中检出新的病灶,并使52.0%患者放疗强化、4.0%患者全身治疗强化。中位随访12.9个月,PSMAgRT组有3例归因于治疗的3级以上不良事件(占接受PSMAgRT患者的2.5%),两组归因于放疗的2级以上不良事件发生率均为43%。

要点

  • PSMA-PET/CT在52.0%患者中导致放疗强化,全身治疗强化仅4.0%。
  • 新病灶检出率:寡转移45.5%、高危39.5%、放疗后挽救14.3%、前列腺切除术后挽救51.6%。
  • 中位随访12.9个月,PSMAgRT组3例归因3级以上事件(2.5%),两组放疗归因2级以上事件均为43%。

核心结论

  • 在这项随机试验中,PSMA-PET/CT使超过一半患者的放疗得到强化。
  • 需要更长的随访来确定这种强化是否转化为对癌症控制、长期毒性及健康相关生活质量结局的影响。

研究设计与样本

  • 这项2期队列多重随机对照试验在2个机构开展,纳入计划接受放疗的前列腺癌患者,按寡转移、高危(癌症前列腺风险评分≥6或cN1)、放疗后挽救和前列腺切除术后挽救4个分层随机分配至PSMAgRT组或对照组。
  • 2018年5月至2021年2月共入组并随机262例患者,后排除9例(对照组5例、PSMAgRT组4例),253例纳入分析(寡转移23例、高危86例、放疗后挽救16例、前列腺切除术后挽救128例)。
  • 主要终点为5年无失败生存,分析有待进一步随访;本报告为次要终点,包括PSMA-PET/CT新病灶检出率、急性和迟发毒性、对前列腺癌管理的影响及健康相关生活质量结局。
  • 试验注册于ClinicalTrials.gov,标识号NCT03525288,与注册研究NCT03378856为姊妹研究。

主要发现

  • 新病灶检出率:寡转移组45.5%、高危组39.5%、放疗后挽救组14.3%、前列腺切除术后挽救组51.6%。
  • 总体而言,PSMA-PET/CT导致52.0%患者放疗强化,全身治疗强化为4.0%。
  • 中位随访12.9个月,放疗强化与3例归因于治疗的3级以上事件相关(占接受PSMAgRT患者的2.5%),但与对照组相比,归因于放疗的2级以上事件发生率无差异(两组均为43%)。

关键数值与推荐

  • 高危分层定义为癌症前列腺风险评分≥6或cN1。
  • 新病灶检出率分别为寡转移45.5%、高危39.5%、放疗后挽救14.3%、前列腺切除术后挽救51.6%。
  • 放疗强化率52.0%,全身治疗强化率4.0%。
  • 中位随访12.9个月,PSMAgRT组归因性3级以上事件3例(占接受PSMAgRT患者的2.5%),两组归因于放疗的2级以上事件发生率均为43%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 主要终点5年无失败生存的分析有待进一步随访。
  • 需要更长的随访来确定放疗强化是否转化为对癌症控制、长期毒性及健康相关生活质量结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prostate-specific membrane antigen (PSMA) ligand positron emission tomography (PET) is increasingly integrated in prostate cancer management because of its diagnostic performance. We sought to evaluate the effect of PSMA-PET/computed tomography (CT)-guided intensification of radiation therapy (PSMAgRT) on patient outcomes. Here, we report secondary trial endpoints including the rate of new lesion detection, effect on prostate cancer management, and treatment-related toxicities. METHODS AND MATERIALS: In this phase 2 cohort multiple randomized controlled trial across 2 institutions, men with prostate cancer planned for RT were randomly selected for PSMAgRT across 4 strata: oligometastatic, high risk (Cancer of the Prostate Risk Assessment ≥6 or cN1), salvage post-RT, and salvage postprostatectomy (RP). Primary endpoint was failure-free survival at 5 years, with analysis pending further follow-up. Secondary endpoints included new lesion detection yield of PSMA-PET/CT, acute and delayed toxicities, effect on prostate cancer management, and health-related quality-of-life outcomes. This trial is registered with ClinicalTrials.gov, identifier NCT03525288, companion to registry NCT03378856. RESULTS: Between May 2018 and February 2021, 262 patients were enrolled and randomized. Nine patients were later excluded (5 control, 4 PSMAgRT), leaving 253 patients for analysis (23 oligometastatic, 86 high risk, 16 salvage post-RT, and 128 salvage post-RP). New lesions were detected in 45.5% of oligometastatic, 39.5% of high risk, 14.3% of salvage post-RT, and 51.6% of salvage post-RP. Overall, PSMA-PET/CT led to intensification of RT in over half of patients (52.0%), with minimal intensification of systemic therapy (4.0%). With a median follow-up of 12.9 months, this intensification was associated with 3 attributable grade 3+ events (2.5% of patients undergoing PSMAgRT) but no difference in the rate of grade 2+ events attributable to RT compared with controls (43%, both arms). CONCLUSIONS: In this randomized trial, PSMA-PET/CT led to intensification of RT in more than half of patients. Longer follow-up is required to determine whether this intensification translates to effect on cancer control and long-term toxicity and health-related quality-of-life outcomes.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Petit C, Delouya G, Taussky D, et al. PSMA-PET/CT-Guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): Findings of Detection Rate, Effect on Cancer Management, and Early Toxicity From a Phase 2 Randomized Controlled Trial. Int J Radiat Oncol Biol Phys. 2023. PMID: 36639035. doi:10.1016/j.ijrobp.2022.12.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。